Menu
25/06/2007
Court challenge over Alzheimer's drugs
A decision by the government's medicines watchdog to refuse to fund Alzheimer's drugs for patients in the early stages of the disease is being challenged in the High Court.
The action has been brought by two drugs companies - Easai and Pfizer - as well as the Alzheimer's Society.
The case centres on three drugs - donepezil, rivastigmine and galantamine. The National Institute for Health and Clinical Excellence (Nice) published guidance last November, which recommended that the drugs should only be prescribed to people in the moderate stages of the disease, because, at a cost of £2.50 per day, they were not cost effective.
Easai, Pfizer and the Alzheimer's Society are arguing that Nice's appraisal process was flawed and unfair.
Neil Hunt, Chief Executive of the Alzheimer's Society, told the BBC: "These treatments have benefited so many families already - where is the justice in Nice's decision to snatch them away?
"We have to fight Nice's fatally flawed process, which has failed to recognise the benefits these treatments have for carers."
However, Andrew Dillon, chief executive of Nice, told the BBC that their processes were "transparent and fair". He said: "The reality is that, for Alzheimer's disease, drugs are only part of the care that needs to be offered.
"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."
The case, which is being heard before Mrs Justice Dobbs at the High Court in London, is expected to last four days.
(KMcA)
The action has been brought by two drugs companies - Easai and Pfizer - as well as the Alzheimer's Society.
The case centres on three drugs - donepezil, rivastigmine and galantamine. The National Institute for Health and Clinical Excellence (Nice) published guidance last November, which recommended that the drugs should only be prescribed to people in the moderate stages of the disease, because, at a cost of £2.50 per day, they were not cost effective.
Easai, Pfizer and the Alzheimer's Society are arguing that Nice's appraisal process was flawed and unfair.
Neil Hunt, Chief Executive of the Alzheimer's Society, told the BBC: "These treatments have benefited so many families already - where is the justice in Nice's decision to snatch them away?
"We have to fight Nice's fatally flawed process, which has failed to recognise the benefits these treatments have for carers."
However, Andrew Dillon, chief executive of Nice, told the BBC that their processes were "transparent and fair". He said: "The reality is that, for Alzheimer's disease, drugs are only part of the care that needs to be offered.
"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."
The case, which is being heard before Mrs Justice Dobbs at the High Court in London, is expected to last four days.
(KMcA)
Related UK National News Stories
Click here for the latest headlines.
01 March 2005
Alzheimer's drugs could be withdrawn
The National Institute of Clinical Excellence (NICE) has recommended the withdrawal of three drugs frequently used to help treat the symptoms of Alzheimer's disease.
Alzheimer's drugs could be withdrawn
The National Institute of Clinical Excellence (NICE) has recommended the withdrawal of three drugs frequently used to help treat the symptoms of Alzheimer's disease.
11 October 2006
Dementia drug appeal rejected
An appeal by Alzheimer's disease groups to win greater access to drugs has been rejected by the NHS watchdog responsible for recommending drugs use. The National institute for Clinical Excellence (NICE) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer�s Disease have not been upheld.
Dementia drug appeal rejected
An appeal by Alzheimer's disease groups to win greater access to drugs has been rejected by the NHS watchdog responsible for recommending drugs use. The National institute for Clinical Excellence (NICE) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer�s Disease have not been upheld.
10 August 2007
Court Orders Review Of Alzheimer's Guidelines
A high court judge has ordered a review of guidelines on the way it decides which Alzheimer's patients are given three drugs to treat the brain-destroying disease.
Court Orders Review Of Alzheimer's Guidelines
A high court judge has ordered a review of guidelines on the way it decides which Alzheimer's patients are given three drugs to treat the brain-destroying disease.
23 January 2006
Anger over Alzheimer's drugs ruling
The revised guidance on drugs for the treatment of Alzheimer's disease has been greeted with anger by Alzheimer's charities.
Anger over Alzheimer's drugs ruling
The revised guidance on drugs for the treatment of Alzheimer's disease has been greeted with anger by Alzheimer's charities.
29 May 2015
23 Charged With Drug Offences Following Raids
More than 20 people have been charged with drug offences following a number of raids carried out in London, Gravesend, Dover and Deal. A total of 23 people were arrested during twenty raids carried out over three days. The suspects, ranging in age from 17 to 52, have all been charged in connection with the supply of class A drugs.
23 Charged With Drug Offences Following Raids
More than 20 people have been charged with drug offences following a number of raids carried out in London, Gravesend, Dover and Deal. A total of 23 people were arrested during twenty raids carried out over three days. The suspects, ranging in age from 17 to 52, have all been charged in connection with the supply of class A drugs.
-
Northern Ireland WeatherToday:There will be a mixture of bright intervals and a few showers. Best of the sunny spells will be near the North Coast. Feeling on the cool side. Maximum temperature 10 °C.Tonight:Showers will gradually die out during the evening. A cold night with long clear spells leading to a touch of frost in places. Minimum temperature 0 °C.
